Eva Pharma, DNAScript, Quantum Biosciences to develop RNA-based vaccine platform in Egypt
Updated 2/6/2025 7:31:00 AM
Arab Finance: Eva Pharma, DNAScript, and Quantum Biosciences have signed a memorandum of understanding (MoU) to establish a comprehensive digital and biological platform for producing RNA-based vaccines and therapeutics in Egypt, as per a statement.
The partnership aims to focus on human and animal health by developing vaccines and therapeutics based on messenger RNA (mRNA) and self-replicating RNA (saRNA).
It will combine DNAScript’s enzymatic DNA synthesis technologies, Quantum Biosciences’ mRNA synthesis technologies (Ntensify®) and Ncapsulate®, and Eva Pharma’s expertise in vaccine development, Good Manufacturing Practices (GMP) sterile manufacturing, and marketing.
The initiative is designed to meet urgent market needs, such as rapid response to infectious disease outbreaks and routine immunizations.
The companies aim to produce 100 million doses of mRNA-based vaccines annually, supporting regional manufacturing autonomy and improving access to biologics.
The partnership aligns with Africa CDC’s goal of producing 60% of vaccines locally by 2040 and the Egyptian Vaccine Manufacturers Alliance (EVMA) target of producing 385 million doses, solidifying Egypt’s position as a global leader in vaccine production.
Related News
